Compare Adaptive Biotechnologies Corp (ADPT) vs Carnival Corp (CCL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Carnival Corp — how do they compare? Adaptive Biotechnologies Corp trades at $20.07 (market cap $3.33B), while Carnival Corp trades at $25.65 (market cap $36.54B). The key difference: Carnival Corp is far larger — about 11× Adaptive Biotechnologies Corp's market cap, and Carnival Corp pays a 1.12% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CCL | |
|---|---|---|
Market Cap | $3.33B | $36.54B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $33.99 |
52-Week Low | $10.24 | $23.89 |
Enterprise Value | $3.19B | $60.47B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Carnival Corporation (CCL) trades at $26.68, down 4.41% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamental recovery with revenue growing to $26.62B in 2025 and net income reaching $2.76B. Positive analyst sentiment exists with a $35.45 consensus price target, though near-term headwinds in European demand and cost pressures are noted.
The outlook for CCL is cautiously optimistic. Strong booking trends and debt reduction support long-term growth, but investors face risks from geopolitical issues, fuel costs, and competitive pressures. The stock presents potential upside from current levels if execution continues, but requires monitoring of guidance and macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Carnival Corp
Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.
Read more on CCL →
